SEC Comment Letter 0000000000-25-002962 to Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc.
Date: March 19, 2025 · CIK: 0001549595 · Accession: 0000000000-25-002962
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39398
Letter
Re: Nurix Therapeutics, Inc. Form 10-K for Fiscal Year Ended November 30, 2024 File No. 001-39398 Dear Hans van Houte:
March 19, 2025
Hans van Houte Chief Financial Officer Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco, CA 94158
We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 19, 2025 Hans van Houte Chief Financial Officer Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco, CA 94158 Re: Nurix Therapeutics, Inc. Form 10-K for Fiscal Year Ended November 30, 2024 File No. 001-39398 Dear Hans van Houte: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>